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ABSTRACT
Quantification methods employing stable isotope-labeled peptide
standards and liquid chromatography–tandem mass spectrometry
are increasingly being used to measure enzyme amounts in biologic
samples. Isoform concentrations, combined with catalytic infor-
mation, can be used in absorption, distribution, metabolism, and
excretion studies to improve accuracy of in vitro/in vivo predictions.
We quantified isoforms of uridine-diphosphate glucuronosyltrans-
ferase (UGT) 1A and 2B in 12 commercially available recombinant
UGTs (recUGTs) (n = 49 samples) using nano-ultra-high-performance
liquid chromatography–tandem mass spectrometry with selected
reaction monitoring). Samples were trypsin-digested and ana-
lyzed using our previously published method. Two MRMs were
collected per peptide and averaged. Where available, at least two
peptides were measured per UGT isoform. The assay could detect
UGTs in all recombinant preparations: recUGTs 1A1, 1A3, 1A4,
1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17, with limit of
detection below 1.0 pmol/mg protein for all isoforms. The assay
had excellent linearity in the range observed (2–15.5 pmol/mg,
after dilution). Examples of concentrations determined were 1465,
537, 538, 944, 865, 698, 604, 791, 382, 1149, 307, and 740 pmol/mg
protein for the respective isoforms. There was a 6.9-fold dif-
ference between the maximum and minimum recUGT concen-
trations. The range of concentrations determined indicates that
catalytic rates per mg total protein in vitro will not accurately
reflect isoform inherent specific activity for a particular drug
candidate. This is the first report of a targeted precise quantifi-
cation of commercially available recUGTs. The assay has po-
tential for use in comparing UGT amounts with catalytic activity
determined using probe substrates, thus allowing representation
of catalysis as per pmol of UGT isoform.
Introduction
Uridine-diphosphate glucuronosyltransferase (UGT) enzymes cata-
lyze formation of the glucuronide conjugates of phase II metabolism
and are important for the elimination of drugs, xenobiotics, and en-
dogenous molecules (Tukey and Strassburg, 2000; Rowland et al.,
2013). In drug development studies potential drug candidates are
tested with a range of metabolic enzymes, including UGTs, to
determine possible routes of disposition. Catalytic activity of enzymes
in the studies is normally presented as amount of substrate converted
per unit of time (e.g., mmol min21) or, for specific activity, the amount
converted per unit of time per amount of total protein in the enzyme
preparation (e.g., mmol min21 mg21) (Court, 2005; Wen et al., 2007).
These units fail to account for differences in the actual amount
of enzyme in a preparation, which is generally only estimated or
unknown. It is suggested, for example, that in recombinant UGT
(recUGT) preparations the UGT content is approximately 5% to 15%
of the total protein content (BD Biosciences, personal communica-
tion). Targeted isotope dilution techniques with tandem mass spec-
trometry have recently been used to quantify a wide range of bioactive
proteins including UGTs, cytochrome P450s, and transporters (Li
et al., 2009; Harbourt et al., 2012; Ohtsuki et al., 2012; Picotti et al.,
2013). The specificity and broad dynamic range of the methods are
advantageous when compared with often semiquantitative, nonspeci-
fic, and expensive traditional immunometric methods (Seppen et al.,
1994; Ritter et al., 1999; Paine and Fisher, 2000; Fallon et al., 2008).
In this study we present application of a previously described capillary
liquid chromatography–tandem mass spectrometry isotope dilution
method (Fallon et al., 2013) for the targeted quantification of up to 14
UGT isoforms to a series of commercially produced recUGT samples
(BD Supersomes [baculovirus-infected insect-cell microsomes]) (12
isoforms; n = 49 samples). We discuss the variation in concentrations
determined between isoforms and between isoform batches, and the
implications of these variations for absorption, distribution, metabo-
lism, and excretion (ADME) studies. We believe that by measuring the
amount of actual isoform in recombinant preparations the catalytic
activity could be more appropriately described in units of activity per
amount of isoform.
Materials and Methods
Materials and Instrumentation. Materials, instrumentation, and methods
were as previously described (Fallon et al., 2013) with slight modifications.
Briefly, synthetic stable isotope-labeled (SIL) proteotypic peptides of known
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concentrations were purchased from Thermo Biopolymers (Ulm, Germany) to
serve as internal standards for calibration. Where possible a minimum of two
peptides were obtained per isoform. Multiple reaction monitoring (MRM)
Pilot (AB SCIEX, Framingham, MA) and Skyline (MacCoss Laboratory,
University of Washington, Seattle, WA) software were used to select and
optimize MRM acquisition parameters on a QTRAP 5500 (AB SCIEX).
Digestion was with trypsin (Promega, Madison, WI), and chromatographic
separation was by nano–ultra-high-performance liquid chromatography (Waters
nanoAcquity, Milford, MA). All recombinant samples were obtained from
a commercial source (BD Supersomes [see description above], BD Biosciences,
San Jose, CA). Rat liver microsomes were from XenoTech, LLC. (Lenexa,
KA). Human liver, kidney, and intestinal microsomes were obtained from
BD Gentest (liver), Celsis IVT Baltimore, MD (kidney and intestine) and
XenoTech, LLC (kidney and intestine). Total protein concentrations were
measured in all samples using the Pierce BCA Protein Assay kit. Results were
adjusted according to variation from the nominal concentrations (Fallon et al.,
2013).
Sample Preparation and Analysis. Recombinant samples (5 mg/ml nomi-
nal protein concentration) were diluted 100-fold with 50 mM ammonium
bicarbonate. To 10 ml aliquots (0.5 mg protein) of each in duplicate was
Fig. 1. TIC and extracted ion chromatogram for digested BD Supersomes recombinant sample UGT1A4-21161, first replicate, including all the stable isotope-labeled
peptide standards and b-casein control peptides. The 100-fold diluted hUGT1A4 concentration represented in the lower panel by the peptide YLSIPAVFFWR was 3.08
pmol/mg protein.
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added ;19 mg of rat liver microsomes to bring the total amount of protein
per sample to ;19.5 mg. Standard to assess tryptic cleavage (b-casein,
0.5 mg) was also added. Samples were reduced with dithiothreitol and de-
natured by heating at 65°C for 40 minutes. Samples were carbamidomethylated
with iodoacetamide and cleaved with trypsin (1:20 w/w) by incubating at
37°C for 4 hours. Reactions were stopped by the addition of acetonitrile
(75 ml), and a pooled solution containing 1 pmol of each SIL proteotypic
UGT peptide standard was added. Following centrifugation the supernatant
was taken to dryness, reconstituted in 50 ml of modified mobile phase A
(2% acetonitrile in water w/ 0.1% formic acid), centrifuged to remove
particulates, and transferred to vials for injection. Sample (2 ml, ,1 mg total
protein digest) was loaded onto a trap column at 15 ml/min for 1 minute, then
eluted through the analytical column at 2 ml/min, from 0–42% B (acetonitrile)
over 24 minutes. The mass spectrometer was equipped with a NanoSpray
III source, and Analyst 1.5 software was used to acquire data via scheduled
MRMs. This analysis used 24 native UGT peptides and 24 SIL UGT pep-
tides, monitored in the method described (Fallon et al., 2013). Two MRMs
were collected per peptide. For each isoform one peptide was used to report
the isoform concentration as previously described (Fallon et al., 2013). For
UGTs 1A3 and 1A8, only one peptide was available for use in the analysis.
For all other isoforms at least two peptides were available (Fallon et al.,
2013).
Treatment of Data, Quantification, and Validation. MultiQuant 2.0.2
software (AB SCIEX) was used for data analysis employing smoothing
(2.0 points; Gaussian Smooth Width) and peak-splitting (2.0 points).
Enzyme isoform concentrations were calculated by comparing the
response for known amount of SIL peptide (1 pmol) with unknown
amount of unlabeled (tryptic) peptide. Responses, following the dilution
(100-fold), were within the linear range. Linearity, inter- and intra-day vari-
ation, and limit of detection were as previously described (Fallon et al.,
2013).
Results
Total and extracted ion chromatograms for a representative sample
(rUGT1A4-21161) are shown in Fig. 1 with addition of standard to
assess tryptic digestion (b-casein). UGTs could be quantified in all
samples (Table 1), with all concentrations of intended UGT isoform
being in the 2.0–15.5 pmol/mg total protein range after 100-fold
dilution. The recombinant UGTs quantified were UGTs 1A1, 1A3,
1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. There
was a 7-fold difference between maximum and minimum average (n = 2)
concentrations determined between all isoforms (maximum and mini-
mum concentration samples are circled in Table 1). S.D. and %CV for
UGT content within batches (duplicates averaged) for the isoforms
listed are shown in Table 1. For UGT1A4 the highest concentration
batch was 77% higher than the lowest concentration batch (Table 1).
Between and within isoform concentration variations are demonstrated
in Fig. 2, A and B. Mean isoform concentrations determined in liver
and kidney microsomes, using the method, are shown in Fig. 2, C and
D (each liver sample was prepared at least in duplicate, and each
kidney sample was prepared five times). UGT concentrations deter-
mined in intestinal microsomes (n = 3; each sample was prepared at
least in duplicate) were 7.5, 3.4, 2.5, and 10.0 pmol/mg protein, re-
spectively, for UGTs 1A1, 1A10, 2B7, and 2B17.
Discussion
The UGT content of a range of commercially available recUGTs
(BD Supersomes, 12 isoforms, n = 49 samples) has been successfully
quantified (Table 1) using a previously described isotope dilution
TABLE 1
recUGT protein concentrations determined in BD Supersomes recombinant samples analyzed in duplicate
One optimal peptide was used for each UGT. The maximum and minimum concentration samples are circled and demonstrate the wide range of concentrations
obtained. Lot numbers are shown in the sample names.
pmol/mg Protein pmol/mg Protein
recUGT Conc. Mean 6 S.D. (%CV) recUGT Conc. Mean 6 S.D. (%CV)
rUGT1A1-1 1359.0 1209.8 6 249.1 (20.6) rUGT1A9-1 441.1 490.5 6 77.7 (15.8)
rUGT1A1-10 rUGT1A9-8 604.3
rUGT1A1-11 914.6 rUGT1A9-9 476.4
rUGT1A1-85244 1101.2 rUGT1A9-06831 440.2
rUGT1A3-1 536.2 473.2 6 75.9 (16.0) rUGT1A10-80018 709.5 738.5 6 45.8 (6.2)
rUGT1A3-9 366.7 rUGT1A10-19244 791.3
rUGT1A3-10 421.3 rUGT1A10-59891 714.7
rUGT1A3-11 504.9
rUGT1A3-12 536.8 rUGT2B4-1 354.4 355.3 6 25.6 (20.6)
rUGT2B4-2 367.6
rUGT1A4-9 537.5 417.3 6 127.5 (30.6) rUGT2B4-3 313.6
rUGT1A4-06150 303.4 rUGT2B4-10714 381.9
rUGT1A4-95375 517.3 rUGT2B4-33191 358.9
rUGT1A4-21161 310.8
rUGT2B7-1 797.7 914.7 6 125.8 (13.8)
rUGT1A6-1 911.8 839.5 6 172.8 (20.6) rUGT2B7-9 918.5
rUGT1A6-7 943.6 rUGT2B7-10 1148.7
rUGT1A6-8 921.6 rUGT2B7-11 926.8
rUGT1A6-04294 581.1 rUGT2B7-12 819.4
rUGT2B7-95853 877.0
rUGT1A7-1 865.0 706.9 6 176.2 (24.9)
rUGT1A7-13906 824.7 rUGT2B15-6 220.4 243.8 6 43.1 (17.7)
rUGT1A7-10729 659.1 rUGT2B15-7 236.8
rUGT1A7-68106 478.9 rUGT2B15-26316 306.5
rUGT2B15-36575
rUGT1A8-7 697.8 598.8 6 96.6 (16.1)
rUGT1A8-05599 504.8 rUGT2B17-1 687.0 708.5 6 28.0 (4.0)
rUGT1A8-21754 593.7 rUGT2B17-2 740.2
rUGT2B17-3 698.2
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targeted quantitative proteomic method (Fallon et al., 2013). This is
the first report of such an analysis and provides additional information
for the use of recUGT and other enzyme preparations in ADME and
drug development studies. The range of concentrations determined sug-
gests that catalytic activity rates measured in vitro per mg of total protein
may not accurately reflect isoform specific activity for a particular drug
candidate, due to wide variability between isoforms and between lots
(batches) of isoforms. The concentrations were found to vary ;7-fold
between isoforms (1,465 versus 211 pmol/mg) (Table 1). An appropriate
use of the data could be to express catalysis as per pmol of UGT isoform,
thus improving knowledge of the substrate activity of new chemical
entities or drugs. The observation of variation between isoform batches
(the highest recUGT1A4 concentration was ;77% higher than the
lowest concentration, [Table 1, Fig. 2B]; this was the highest variation
observed) further indicates the possible limitation of the assumption of
uniform isoform content, including when considered in relation to
isoform kinetics.
A multiplexed (Fig. 1) targeted precise method for quantification
such as this has broad applicability in ADME and in the support of
drug development. The method allows the quantification of proteins
involved in drug disposition, including recUGTs, that have not been
previously measurable using traditional immunologically based meth-
ods (Fallon et al., 2008; Li et al., 2009; Harbourt et al., 2012). The
equivalence of recUGT and organ-specific UGT (hepatic, intestinal,
renal) catalytic rates on a per pmol basis (Fig. 2, C and D), employing
the data presented here, is currently being determined. However, vari-
ation is expected due to, for example, posttranslational modifications
or protein interactions within the membrane. The prospect of employing
enzyme catalytic activity measurements denoted as per amount of en-
zyme isoform in ADME studies is accordingly feasible. The availability
of concentration/abundance data for UGTs in recombinant systems
and tissue fractions should prove useful for scientists attempting to
determine intersystem extrapolation factors, or more specifically, to
determine fractional metabolism by UGTs or attempt in vitro–in vivo
extrapolation. In addition, the development of physiologically based
pharmacokinetic models where interindividual variation of UGT abun-
dance in hepatic or extrahepatic drug-metabolizing organs is incor-
porated depends on knowledge of enzyme abundance in the relevant
drug-clearing tissues.
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Fig. 2. UGT protein concentrations in (A) BD Supersomes UGT1A1 samples analyzed in duplicate (n = 4), (B) BD Supersomes UGT1A4 samples in duplicate (n = 4), (C)
a library of BD Gentest human liver microsome samples (mean, n = 60), and (D) human kidney microsome samples (mean, n = 2). Each liver and kidney sample was
analyzed at least in duplicate.
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